4.2 Article

Whole-body vibration training in children with Duchenne muscular dystrophy and spinal muscular atrophy

Journal

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
Volume 18, Issue 2, Pages 140-149

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejpn.2013.09.005

Keywords

Whole-body vibration training; Exercise in neuromuscular diseases; Duchenne muscular dystrophy; Spinal muscular atrophy; Creatine kinase

Funding

  1. Baden-Wurttemberg State Ministry of Science, Research and the Arts

Ask authors/readers for more resources

Introduction: Whole-body-vibration training is used to improve muscle strength and function and might therefore constitute a potential supportive therapy for neuromuscular diseases. Objective: To evaluate safety of whole-body vibration training in ambulatory children with Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). Methods: 14 children with DMD and 8 with SMA underwent an 8-week vibration training programme on a Galileo MedM (R) at home (3 x 3 min twice a day, 5 days a week). Primary outcome was safety of the training, assessed clinically and by measuring serum creatine kinase levels. Secondary outcome was efficacy as measured by changes in time function tests, muscle strength and angular degree of dorsiflexion of the ankles. Results: All children showed good clinical tolerance. In boys with DMD, creatine kinase increased by 56% after the first day of training and returned to baseline after 8 weeks of continuous whole-body vibration training. No changes in laboratory parameters were observed in children with SMA. Secondary outcomes showed mild, but not significant, improvements with the exception of the distance walked in the 6-min walking test in children with SMA, which rose from 371.3 m to 402.8 m (p < 0.01). Interpretation: Whole-body vibration training is clinically well tolerated in children with DMD and SMA. The relevance of the temporary increase in creatine kinase in DMD during the first days of training is unclear, but it is not related to clinical symptoms or deterioration. (C) 2013 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available